Literature DB >> 25122673

Calcineurin determines toxic versus beneficial responses to α-synuclein.

Gabriela Caraveo1, Pavan K Auluck2, Luke Whitesell3, Chee Yeun Chung3, Valeriya Baru1, Eugene V Mosharov4, Xiaohui Yan5, Manu Ben-Johny6, Martin Soste7, Paola Picotti7, Hanna Kim5, Kim A Caldwell5, Guy A Caldwell5, David Sulzer8, David T Yue6, Susan Lindquist9.   

Abstract

Calcineurin (CN) is a highly conserved Ca(2+)-calmodulin (CaM)-dependent phosphatase that senses Ca(2+) concentrations and transduces that information into cellular responses. Ca(2+) homeostasis is disrupted by α-synuclein (α-syn), a small lipid binding protein whose misfolding and accumulation is a pathological hallmark of several neurodegenerative diseases. We report that α-syn, from yeast to neurons, leads to sustained highly elevated levels of cytoplasmic Ca(2+), thereby activating a CaM-CN cascade that engages substrates that result in toxicity. Surprisingly, complete inhibition of CN also results in toxicity. Limiting the availability of CaM shifts CN's spectrum of substrates toward protective pathways. Modulating CN or CN's substrates with highly selective genetic and pharmacological tools (FK506) does the same. FK506 crosses the blood brain barrier, is well tolerated in humans, and is active in neurons and glia. Thus, a tunable response to CN, which has been conserved for a billion years, can be targeted to rebalance the phosphatase's activities from toxic toward beneficial substrates. These findings have immediate therapeutic implications for synucleinopathies.

Entities:  

Keywords:  Crz1; NFAT; Slm2; TORC2; neuroinflammation

Mesh:

Substances:

Year:  2014        PMID: 25122673      PMCID: PMC4151770          DOI: 10.1073/pnas.1413201111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  66 in total

1.  α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases.

Authors:  Zane S Martin; Volker Neugebauer; Kelly T Dineley; Rakez Kayed; Wenru Zhang; Lindsay C Reese; Giulio Taglialatela
Journal:  J Neurochem       Date:  2011-11-28       Impact factor: 5.372

2.  Hph1 and Hph2 are novel components of the Sec63/Sec62 posttranslational translocation complex that aid in vacuolar proton ATPase biogenesis.

Authors:  Francisco J Piña; Allyson F O'Donnell; Silvere Pagant; Hai Lan Piao; John P Miller; Stanley Fields; Elizabeth A Miller; Martha S Cyert
Journal:  Eukaryot Cell       Date:  2010-11-19

3.  A modular switch for spatial Ca2+ selectivity in the calmodulin regulation of CaV channels.

Authors:  Ivy E Dick; Michael R Tadross; Haoya Liang; Lai Hock Tay; Wanjun Yang; David T Yue
Journal:  Nature       Date:  2008-01-30       Impact factor: 49.962

4.  A novel immunophilin ligand: distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease.

Authors:  L C Costantini; P Chaturvedi; D M Armistead; P G McCaffrey; T W Deacon; O Isacson
Journal:  Neurobiol Dis       Date:  1998-08       Impact factor: 5.996

Review 5.  Interaction of calcineurin with substrates and targeting proteins.

Authors:  Huiming Li; Anjana Rao; Patrick G Hogan
Journal:  Trends Cell Biol       Date:  2010-11-04       Impact factor: 20.808

6.  Functional analysis of VPS41-mediated neuroprotection in Caenorhabditis elegans and mammalian models of Parkinson's disease.

Authors:  Adam J Harrington; Talene A Yacoubian; Sunny R Slone; Kim A Caldwell; Guy A Caldwell
Journal:  J Neurosci       Date:  2012-02-08       Impact factor: 6.167

7.  alpha-Synuclein exhibits competitive interaction between calmodulin and synthetic membranes.

Authors:  Daekyun Lee; Sun-Young Lee; Eui-Nam Lee; Chung-Soon Chang; Seung R Paik
Journal:  J Neurochem       Date:  2002-09       Impact factor: 5.372

Review 8.  Olfactory dysfunction in Parkinson disease.

Authors:  Richard L Doty
Journal:  Nat Rev Neurol       Date:  2012-05-15       Impact factor: 42.937

9.  Use of calcium channel blockers and Parkinson's disease.

Authors:  Björn Pasternak; Henrik Svanström; Nete M Nielsen; Lars Fugger; Mads Melbye; Anders Hviid
Journal:  Am J Epidemiol       Date:  2012-03-01       Impact factor: 4.897

10.  The Ca2+/Mn2+ ion-pump PMR1 links elevation of cytosolic Ca(2+) levels to α-synuclein toxicity in Parkinson's disease models.

Authors:  S Büttner; L Faes; W N Reichelt; F Broeskamp; L Habernig; S Benke; N Kourtis; D Ruli; D Carmona-Gutierrez; T Eisenberg; P D'hooge; R Ghillebert; V Franssens; A Harger; T R Pieber; P Freudenberger; G Kroemer; S J Sigrist; J Winderickx; G Callewaert; N Tavernarakis; F Madeo
Journal:  Cell Death Differ       Date:  2012-11-16       Impact factor: 12.067

View more
  58 in total

1.  Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress.

Authors:  Jaime N Guzman; Ema Ilijic; Ben Yang; Javier Sanchez-Padilla; David Wokosin; Dan Galtieri; Jyothisri Kondapalli; Paul T Schumacker; D James Surmeier
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

Review 2.  Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease.

Authors:  D James Surmeier; Glenda M Halliday; Tanya Simuni
Journal:  Exp Neurol       Date:  2017-08-02       Impact factor: 5.330

Review 3.  Selective neuronal vulnerability in Parkinson disease.

Authors:  D James Surmeier; José A Obeso; Glenda M Halliday
Journal:  Nat Rev Neurosci       Date:  2017-01-20       Impact factor: 34.870

4.  Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain.

Authors:  Amber Tariq; JiaBei Lin; Megan M Noll; Mariana P Torrente; Korrie L Mack; Oscar Hernandez Murillo; Meredith E Jackrel; James Shorter
Journal:  FEMS Yeast Res       Date:  2018-08-01       Impact factor: 2.796

Review 5.  Coherent and Contradictory Facts, Feats and Fictions Associated with Metal Accumulation in Parkinson's Disease: Epicenter or Outcome, Yet a Demigod Question.

Authors:  Mohd Sami Ur Rasheed; Sonam Tripathi; Saumya Mishra; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2016-08-01       Impact factor: 5.590

Review 6.  An emerging role of astrocytes in vascular contributions to cognitive impairment and dementia.

Authors:  Brittani R Price; Christopher M Norris; Pradoldej Sompol; Donna M Wilcock
Journal:  J Neurochem       Date:  2018-01-22       Impact factor: 5.372

7.  From Yeast to Humans: Leveraging New Approaches in Yeast to Accelerate Discovery of Therapeutic Targets for Synucleinopathies.

Authors:  Jeff S Piotrowski; Daniel F Tardiff
Journal:  Methods Mol Biol       Date:  2019

8.  Genome-Scale Networks Link Neurodegenerative Disease Genes to α-Synuclein through Specific Molecular Pathways.

Authors:  Vikram Khurana; Jian Peng; Chee Yeun Chung; Pavan K Auluck; Saranna Fanning; Daniel F Tardiff; Theresa Bartels; Martina Koeva; Stephen W Eichhorn; Hadar Benyamini; Yali Lou; Andy Nutter-Upham; Valeriya Baru; Yelena Freyzon; Nurcan Tuncbag; Michael Costanzo; Bryan-Joseph San Luis; David C Schöndorf; M Inmaculada Barrasa; Sepehr Ehsani; Neville Sanjana; Quan Zhong; Thomas Gasser; David P Bartel; Marc Vidal; Michela Deleidi; Charles Boone; Ernest Fraenkel; Bonnie Berger; Susan Lindquist
Journal:  Cell Syst       Date:  2017-01-25       Impact factor: 10.304

9.  Therapeutic genetic variation revealed in diverse Hsp104 homologs.

Authors:  Katelyn Sweeney; Hanna Kim; Xiaohui Yan; Zachary M March; Laura M Castellano; Meredith E Jackrel; JiaBei Lin; Edward Chuang; Edward Gomes; Corey W Willicott; Karolina Michalska; Robert P Jedrzejczak; Andrzej Joachimiak; Kim A Caldwell; Guy A Caldwell; Ophir Shalem; James Shorter
Journal:  Elife       Date:  2020-12-15       Impact factor: 8.140

Review 10.  Calcium and Parkinson's disease.

Authors:  D James Surmeier; Paul T Schumacker; Jaime D Guzman; Ema Ilijic; Ben Yang; Enrico Zampese
Journal:  Biochem Biophys Res Commun       Date:  2016-08-30       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.